Proteinase 3: A cofactor for the binding of antineutrophil cytoplasm antibodies (ANCA) to endothelial cells?  by Tervaert, Jan Willem Cohen
Kidney International, Vol. 57 (2000), pp. 2171–2172
EDITORIAL
Proteinase 3: A cofactor for the binding of antineutrophil
cytoplasm antibodies (ANCA) to endothelial cells?
Endothelial cells line all blood vessels of the body and tion on endothelial cells, and subsequently engagement
potentially contribute to the pathophysiology of vasculi- of Fc gamma receptors on circulating PMN.
tides that are associated with anti-neutrophil cytoplasmic In many different studies, antibodies that bind to cul-
autoantibodies (ANCA) directed to proteinase 3 (PR3) tured endothelial cells have been demonstrated in pa-
or myeloperoxidase (MPO). Histopathologic findings in tients with ANCA-associated vasculitides [5–8]. Impor-
patients with these forms of vasculitis include intravascu- tantly, these antibodies not only bind to endothelial cells
lar-activated polymorphonuclear neutrophils (PMN) but also activate these cells, resulting in the increased
that are present at areas of endothelial cell lysis and expression of adhesion molecules and secretion of tissue
detachment [1]. factor, different cytokines and chemotactic factors [6–8].
These observations are consistent with the hypothesis Finally, it has been shown that pretreatment of the cul-
that intravascular activation of leukocytes that are in close tured endothelial cells with TNF-a or IL-1 results in
contact with endothelial cells are responsible for endothe- increased autoantibody binding and further enhance-
lial injury in ANCA-associated vasculitides. Indeed, in ment of endothelial cell activation [5, 9].
vitro studies have demonstrated that ANCA-stimulated A question that puzzles many researchers is: what are
PMN are capable of damaging endothelial cells [2, 3]. the antigens that are recognized by the antibodies that
In in vitro studies it has also been demonstrated that bind to and activate endothelial cells?
PMN need to be “primed” before they can be activated Purified IgG from most patients with ANCA-associ-
by ANCA. This process of priming occurs through in- ated vasculitis that induce endothelial cell activation rec-
flammatory mediators such as tumor necrosis factor ognize antigens on endothelial cells that are not well
alpha (TNF-a), interleukin-1 (IL-1) or IL-8, and results characterized [6–8]. In addition, however, several groups
in, among other effects, surface expression of PR3 and reported that affinity purified PR3-ANCA could also
MPO, making these target antigens available for interac- bind to and activate endothelial cells, and that this inter-
tion with ANCA [4]. If these primed PMN are subse- action could be blocked by pre-incubation with purified
quently activated by ANCA, the activated PMN do what PR3 [9–11], suggesting the presence of PR3 on the cell
all activated PMN are capable of: they produce and se- surface of endothelial cells. Indeed, Mayet et al demon-
crete reactive oxygen species, they degranulate lyso- strated that fixed cultured endothelial cells reacted with
somal enzymes, including PR3, MPO, and elastase, and antibodies to proteinase 3, and that during cytokine
they produce inflammatory mediators, such as TNF-a, treatment of the endothelial cells PR3 became expressed
IL-1, IL-8, and leukotriene B4, which may in turn prime on the cell surface of endothelial cells [12]. These results
or attract other cells. Furthermore, when this ANCA- were confirmed by some groups [9, 11] but not by others
induced activation of PMN takes place at the time that [13, 14]. Pendergraft et al in this tissue of Kidney Interna-
these PMN adhere to endothelial cells, vascular injury tional also report that they were not able to detect PR3
follows [4]. protein in cultured endothelial cells [15]. A possible ex-
An important question is how are these PMN attracted planation for these different results may be that the de-
to the endothelium? Two routes have to be considered: tection of PR3 on endothelial cells is very sensitive to
(a) regulation via adhesion receptors. Activation of en- handling of the endothelial cells [11, 14]. Several groups
dothelial cells results in the increased expression of selec- have demonstrated that the addition of PR3 to cultured
tins and cell adhesion molecules on endothelial cells that endothelial cells results in binding of PR3 to endothelial
are interacting with their complementary adhesion re- cells. Moreover, endothelial-bound PR3 can be recog-
ceptors on circulating PMN. (b) Regulation via Fc nized by anti-PR3 antibodies [reviewed in 8]. Recently,
gamma receptors as a result of immunoglobulin deposi- Taekema-Roelvink and Daha demonstrated that the in-
teraction of PR3 with endothelial cells is receptor medi-
ated and may result in activation of endothelial cells [14].Key words: vasculides, PR3-ANCA, cell binding, free radical injury,
inflammation. So, the demonstration of PR3 synthesis by endothelial
cells is crucial to solve the issue of whether PR3-ANCAÓ 2000 by the International Society of Nephrology
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